Saracatinib

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：Saracatinib	Purity：98% min
CAS NO：379231-04-6	Solubility：DMSO : ≥ 32 mg/mL (59.04 mM)
Molecular Formula：C₂₇H₃₂ClN₅O₅	Package：Package according to customer requirements
Molecular Weight：542.026	Storage：Store at -20℃

Quality control

Remarks

Saracatinib, also known as AZD0530, is an orally available dual-specific inhibitor of Src and Abl with anti-invasive and anti-tumor activities. Src and Abl are protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. Saracatinib binds to and inhibits these tyrosine kinases and their effects on cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival.

Related Products:

Afatinib dimaleate; Neratinib; Bosutinib; Bosutinib Intermediates; Bosutinib Monohydrate; Dasatinib; NVP-BHG712; PP1; PP2; A-966492; G007-LK; SU6656; Tirbanibulin; TPX-0005; Afatinib

References

[1]. Green TP, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol, 2009, 3(3), 248-261.

[2]. Fuse MA, et al. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol Cancer Ther. Mol Cancer Ther. 2017 Nov;16(11):2387-2398.